Eligible procedures in the ADAPT-1 and ADAPT-2 studies1:

  • Biliary interventions
  • Bronchoscopy +/- biopsy
  • Chemoembolization for HCC
  • Colonoscopy +/- polypectomy/biopsy
  • Dental procedures
  • Ethanol ablation
  • Laparoscopic interventions
  • Liver biopsy
  • Nephrostomy tube placement
  • Paracentesis
  • Radiofrequency ablation
  • Renal biopsy
  • Thoracentesis
  • Transjugular intrahepatic portosystemic shunt
  • Upper GI endoscopy +/- biopsy
  • Upper GI endoscopy +/- sclerotherapy
  • Upper GI endoscopy +/- variceal banding
  • Vascular catheterization

 

In the ADAPT studies, the percentage of patients who underwent procedures with low, moderate, or high risk was as follows: Low, 60.8%; Moderate, 17.2%; and High, 22.1%.2

ADAPT-1 and ADAPT-2 were 2 identically designed, multicenter, randomized, double-blind, placebo-controlled studies (N=435)2

ADAPT-1 and ADAPT-2 Phase III study design to evaluate the efficacy and safety of DOPTELET

DOPTELET (avatrombopag) HELPS PROTECT PATIENTS DURING AND AFTER A SCHEDULED PROCEDURE

Significantly reduced the need for platelet transfusions or rescue procedures for bleeding for up to 7 days post procedure2*

88% of high-baseline patients and up to 69% of low-baseline patients taking DOPTELET achieved the primary endpoint (N=435)

DOPTELET HELPS PROTECT PATIENTS DURING AND AFTER A SCHEDULED PROCEDURE

 

Primary Endpoint: Patients not requiring a platelet transfusion or any rescue procedure for bleeding up to 7 days following a scheduled procedure2

*From randomization of DOPTELET 40 mg or DOPTELET 60 mg once daily for 5 days up to 7 days after a procedure, compared to placebo (P<.001; N=435).2

MEAN PLATELET COUNTS NEARLY DOUBLED WITH DOPTELET (avatrombopag)

With DOPTELET, platelet counts significantly increased by procedure day2

Up to +45,000 in high-baseline patients and +32,000 in low-baseline patients2

Mean platelet counts nearly doubled with DOPTELET

97% of patients with a platelet count measured on procedure day had an increase with DOPTELET3

WITH DOPTELET (avatrombopag), PATIENTS CAN BE READY FOR PROCEDURE DAY WITH ≥50,000/μL PLATELETS

Significantly more patients achieved a platelet count of ≥50,000/μL with DOPTELET2

Up to 93% of high-baseline patients and 69% of low-baseline patients reached the 50,000/μL target (N=435)2

WITH DOPTELET, PATIENTS CAN BE READY FOR PROCEDURE DAY WITH ≥50,000/μL PLATELETS

References:

1. Terrault N, Chen Y-C, Izumi N, et al. Avatrombopag before procedures reduces need for platelet transfusion in patients with chronic liver disease and thrombocytopenia. Gastroenterology. 2018;155(3):705-718.

2. DOPTELET [package insert]. Durham, NC: Dova Pharmaceuticals, Inc; 2018.

3. Data on file. Dova Pharmaceuticals, Inc.